Clinical Trials Logo
  1. Home
  2. Pancreatic Cancer Non-resectable
  3. NCT03165591

Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer — V3-P  

Pancreatic Cancer Non-resectable Clinical Trial

Official title:
Open Label Phase II Immunotherapy Trial of Inoperable Pancreatic Cancer

Clinical Trial Summary

Pancreatic cancer (PDA) is the most lethal form of cancer, and the fourth-leading cause of cancer-related death in the United States, with a survival rate of less than 7%.There are currently no treatments found to be effective for patients with advanced disease who are ineligible for surgery, a prognosis representing the majority of pancreatic cancer diagnoses. Pancreatic cancer is not amenable to chemotherapy as compared to other cancer types, leaving patients with practically no options except surgery.

We have made oral tableted therapeutic vaccine, V3-P, derived from pooled blood of patients with PDA in line with similar highly promising approach we have adopted for patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CAA). Patients with PDA will be given one tablet per day of V3-P and followed up to see the outcome.

Clinical Trial Description

This study is an open label Phase II study aimed to recruit at least 20 patients with inoperable PDA and who are positive for CA19.9 pancreatic tumor marker. The presence of higher than normal levels of CA19.9 is the sole inclusion criteria. Patients will be given one tablet of V3-P daily and followed for three months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03165591
Study type Interventional
Source Immunitor LLC
Contact aldar Bourinbaiar, MD/PhD, PhD
Phone +976-95130306
Email immunitor@gmail.com
Status Recruiting
Phase Phase 1/Phase 2
Start date May 1, 2017
Completion date December 31, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02128100 - Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT05047991 - Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Phase 2
Completed NCT03590275 - Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX
Recruiting NCT05265663 - Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients N/A
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06160323 - Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer N/A
Active, not recruiting NCT04156087 - Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT03941093 - Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer Phase 3
Recruiting NCT05549414 - Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System N/A
Withdrawn NCT04852367 - PanDox: Targeted Doxorubicin in Pancreatic Tumours Phase 1
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Recruiting NCT03964064 - I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer N/A
Not yet recruiting NCT06361030 - Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT05424159 - Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer N/A
Terminated NCT01887041 - Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer Phase 4
Active, not recruiting NCT03984214 - Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer Phase 3
Recruiting NCT05262452 - Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer N/A
Recruiting NCT04986930 - mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma Phase 2
Recruiting NCT04116073 - INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer Phase 2
Not yet recruiting NCT05802485 - PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT N/A